Peptisource

Tirzepatid 45mg

Tirzepatid, a synthetic polypeptide drug, is the first dual agonist of GLP - 1 and GIP receptors. Given via once - weekly subcutaneous injection, it regulates blood glucose through a dual - action mechanism. Activating GLP - 1 receptor promotes insulin secretion and inhibits glucagon release, while GIP receptor activation boosts insulin sensitivity and secretion.It also delays gastric emptying, increases satiety, reduces food intake, and helps with weight loss. Additionally, it raises adiponectin levels, improving insulin sensitivity and lipid metabolism.Clinical trials show Tirzepatid is better than single GLP - 1 agonists in blood glucose control, significantly lowering HbA1c. It's effective for weight loss (average > 20%) and obesity treatment. The once - weekly injection improves patient compliance, and it has fewer side - effects. It also benefits blood pressure and lipid profile, showing potential cardioprotection.

Spec: 45mg
Packaging: 1kits（10Vials）
$340USD
1

▎Tirzepatid Overview


Tirzepatid, a synthetic polypeptide drug, is the first dual agonist of GLP - 1 and GIP receptors. Given via once - weekly subcutaneous injection, it regulates blood glucose through a dual - action mechanism. Activating GLP - 1 receptor promotes insulin secretion and inhibits glucagon release, while GIP receptor activation boosts insulin sensitivity and secretion.It also delays gastric emptying, increases satiety, reduces food intake, and helps with weight loss. Additionally, it raises adiponectin levels, improving insulin sensitivity and lipid metabolism.Clinical trials show Tirzepatid is better than single GLP - 1 agonists in blood glucose control, significantly lowering HbA1c. It's effective for weight loss (average > 20%) and obesity treatment. The once - weekly injection improves patient compliance, and it has fewer side - effects. It also benefits blood pressure and lipid profile, showing potential cardioprotection.


In conclusion, with its innovative mechanism and good results, Tirzepatid offers new treatment options for type 2 diabetes and obesity patients, promising to improve their quality of life and health.